<DOC>
	<DOC>NCT01261494</DOC>
	<brief_summary>This study is expected to demonstrate the anti-diabetic efficacy of 3-months treatment with GFT505 (80 mg/d) on Glycosylated Haemoglobin A1c (HbA1C) and fasting plasma glucose. And to assess the tolerability and safety of once-a-day administrations of oral doses of GFT505 for 12 weeks in patients with type 2 diabetes mellitus.</brief_summary>
	<brief_title>Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>The study period per patient is 16-20 weeks maximum and is conducted as follows : - Run-in period: 2 weeks or 6 weeks for patients under fibrate treatment at screening (4 weeks fibrate wash-out + 2 weeks placebo run-in); - Treatment period: 12 weeks; - Follow-up period: 2 weeks.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Male or postmenopausal female (defined as &gt;12 months since last menstrual period) or surgical menopause. If hormonal replacement therapy, it should be stable at least for 6 months prior to screening. Body Mass Index ≥27 and ≤45 kg/m². DrugNaive patients with type 2 diabetes mellitus (non insulin dependent diabetes). Patients should not be treated by insulin or other diabetes medication for the last 3 months prior to screening. Patients treated for less than 4 weeks with insulin may be included in the study. HbA1c ≥ 7.0% and &lt;9.5%. Antibody glutamate decarboxylase acid (AntiGAD) negative for patients aged less than 40 years. Type I Diabetes Mellitus. Blood Pressure &gt; 160 / 95 mmHg. Lipidlowering drugs such as fibrates. Fasting Plasma Glucose (FPG) ≥ 240 mg/dL. Triglycerides (TG) &gt; 400 mg/dL.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Diabetes Mellitus, Type 2</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>PPARs</keyword>
	<keyword>OGTT</keyword>
</DOC>